Kiromic develops biomarker- and small molecule-based diagnostic and therapeutic programs specifically targeting solid tumors and hematologic malignancies. The company addresses the limitations of current immunotherapy options, which often result in poor patient outcomes and harmful off-target effects.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current immunotherapy options for treating solid tumors and hematologic malignancies often lead to poor patient outcomes and harmful off-target effects, limiting their effectiveness. A significant percentage of cancer deaths in the US are potentially treatable by immunotherapy drugs, but lack current approval for immunotherapy.
Solution
Kiromic Biopharma develops diagnostic and therapeutic programs based on biomarkers and small molecules, specifically designed to target solid tumors and hematologic malignancies. The company aims to improve patient outcomes by addressing the limitations of existing immunotherapy approaches. Kiromic's approach seeks to reduce toxicities and off-target effects that harm normal cells, which are commonly associated with conventional cancer therapies.
Target Audience
The primary target audience includes patients with solid tumors and hematologic malignancies who are eligible for immunotherapy, as well as healthcare providers specializing in oncology.
Features
- Development of biomarker-based diagnostic programs for cancer.
- Development of small molecule-based therapeutic programs for cancer.
- Focus on solid tumors and hematologic malignancies.
- Aims to improve the efficacy and safety of immunotherapy.